» Authors » Claes Held

Claes Held

Explore the profile of Claes Held including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 227
Citations 11150
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Leissner P, Olsson E, Rondung E, Sundelin R, Spaak J, Ulvenstam A, et al.
Eur J Prev Cardiol . 2025 Feb; PMID: 39999037
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) and takotsubo syndrome (TS) are both characterised by lack of significant coronary artery stenoses and a higher prevalence of mental health disorders...
2.
Arslani K, Engstrom T, Maeng M, Kjoller-Hansen L, Maehara A, Zhou Z, et al.
JACC Cardiovasc Imaging . 2025 Feb; PMID: 39998456
Background: Hemodynamically obstructive coronary plaques may contain more vulnerable plaque characteristics than nonobstructive lesions. Objectives: The authors aimed to assess whether pressure-wire-based physiologic indices in nonculprit lesions are associated with...
3.
Leissner P, Mars K, Humphries S, Jernberg T, Held C, Hofmann R, et al.
Gen Hosp Psychiatry . 2025 Feb; 94:26-32. PMID: 39983429
Objective: Cardiac anxiety (CA) is common and has been associated with increased morbidity and mortality in patients after acute myocardial infarction (AMI). While beta-blockers are widely used in secondary prevention...
4.
Hag E, Back M, Henriksson P, Wallert J, Held C, Stomby A, et al.
Eur J Cardiovasc Nurs . 2025 Jan; 24(2):253-263. PMID: 39743227
Aims: Improved dietary habits are important for successful secondary prevention after myocardial infarction (MI), with counselling and support on healthy dietary habits constituting a cornerstone of cardiac rehabilitation (CR). However,...
5.
6.
Erlinge D, Andersson J, Frobert O, Tornerud M, Hamid M, Kellerth T, et al.
Lancet . 2024 Oct; 404(10464):1750-1759. PMID: 39481425
Background: Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention (PCI) remain a challenge. A bioadaptor is a novel implant that addresses this issue by restoring the...
7.
Leissner P, Mars K, Humphries S, Karlstrom P, Yndigegn T, Jernberg T, et al.
Eur Heart J Acute Cardiovasc Care . 2024 Oct; 13(11):789-797. PMID: 39422765
Aims: Among patients with myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI trial did not demonstrate a benefit of beta-blocker vs. no beta-blocker treatment on all-cause...
8.
Kjoller-Hansen L, Maehara A, Kelbaek H, Matsumura M, Maeng M, Engstrom T, et al.
Circ Cardiovasc Interv . 2024 Sep; 17(10):e014215. PMID: 39319453
Background: Lipid content in untreated nonobstructive coronary artery lesions is associated with adverse clinical outcomes, and residual in-stent or stent edge lipid may worsen outcomes after percutaneous coronary intervention (PCI)....
9.
Lund L, James S, DeVore A, Anstrom K, Fudim M, Aaronson K, et al.
Eur J Heart Fail . 2024 Sep; 26(11):2453-2463. PMID: 39282788
Aims: Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive....
10.
Mars K, Humphries S, Leissner P, Jonsson M, Karlstrom P, Lauermann J, et al.
Eur Heart J Cardiovasc Pharmacother . 2024 Sep; 10(8):708-718. PMID: 39217445
Aims: In the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) study, long-term beta-blocker use in patients after acute myocardial infarction (AMI) with preserved left ventricular...